Kostas Biliouris
Stock Analyst at Oppenheimer
(1.02)
# 3,770
Out of 4,534 analysts
427
Total ratings
38.6%
Success rate
-0.7%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NRIX Nurix Therapeutics | Maintained: Buy | $28 | $23.12 | +21.11% | 2 | Jul 10, 2026 | |
| PRQR ProQR Therapeutics | Maintained: Buy | $9 | $1.70 | +429.41% | 3 | Jul 6, 2026 | |
| ALNY Alnylam Pharmaceuticals | Reiterated: Buy | $500 | $267.47 | +86.94% | 39 | Jun 25, 2026 | |
| IRD Opus Genetics | Reiterated: Buy | $10 | $3.27 | +205.81% | 2 | Jun 17, 2026 | |
| LEGN Legend Biotech | Maintained: Buy | $75 | $22.26 | +236.93% | 59 | Jun 15, 2026 | |
| DSGN Design Therapeutics | Reiterated: Buy | $21 | $12.57 | +67.06% | 4 | Jun 15, 2026 | |
| DTIL Precision BioSciences | Initiated Coverage: Buy | $20 | $7.87 | +154.13% | 21 | Jun 9, 2026 | |
| TRDA Entrada Therapeutics | Reiterated: Buy | $23 | $6.89 | +233.82% | 4 | Jun 3, 2026 | |
| EVMN Evommune | Reiterated: Buy | $50 | $12.14 | +311.86% | 3 | May 15, 2026 | |
| PRME Prime Medicine | Reiterated: Buy | $11 | $3.13 | +251.44% | 18 | May 12, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $37 | $17.22 | +114.87% | 37 | May 7, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $56.03 | $12.29 | +355.92% | 2 | Apr 20, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $15 | $2.25 | +566.67% | 3 | Mar 31, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $22 | $12.25 | +79.59% | 18 | Mar 13, 2026 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $59.59 | - | 31 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $54.39 | - | 27 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $3.44 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $11.38 | - | 25 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $81.38 | - | 12 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $27.53 | - | 23 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $0.885 | - | 4 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $23.74 | - | 5 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.50 | - | 14 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $10.99 | - | 30 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $1.24 | - | 9 | Sep 25, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterated: Buy | $75 | $47.78 | +56.97% | 20 | Sep 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Rated: Hold | n/a | $5.18 | n/a | 6 | Jan 29, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiated Coverage: Buy | $77 | $303.39 | n/a | 1 | Jun 16, 2022 |
Nurix Therapeutics
Jul 10, 2026
Maintained: Buy
Price Target: $28
Current: $23.12
Upside: +21.11%
ProQR Therapeutics
Jul 6, 2026
Maintained: Buy
Price Target: $9
Current: $1.70
Upside: +429.41%
Alnylam Pharmaceuticals
Jun 25, 2026
Reiterated: Buy
Price Target: $500
Current: $267.47
Upside: +86.94%
Opus Genetics
Jun 17, 2026
Reiterated: Buy
Price Target: $10
Current: $3.27
Upside: +205.81%
Legend Biotech
Jun 15, 2026
Maintained: Buy
Price Target: $75
Current: $22.26
Upside: +236.93%
Design Therapeutics
Jun 15, 2026
Reiterated: Buy
Price Target: $21
Current: $12.57
Upside: +67.06%
Precision BioSciences
Jun 9, 2026
Initiated Coverage: Buy
Price Target: $20
Current: $7.87
Upside: +154.13%
Entrada Therapeutics
Jun 3, 2026
Reiterated: Buy
Price Target: $23
Current: $6.89
Upside: +233.82%
Evommune
May 15, 2026
Reiterated: Buy
Price Target: $50
Current: $12.14
Upside: +311.86%
Prime Medicine
May 12, 2026
Reiterated: Buy
Price Target: $11
Current: $3.13
Upside: +251.44%
May 7, 2026
Reiterated: Buy
Price Target: $37
Current: $17.22
Upside: +114.87%
Apr 20, 2026
Reiterated: Buy
Price Target: $56.03
Current: $12.29
Upside: +355.92%
Mar 31, 2026
Reiterated: Buy
Price Target: $15
Current: $2.25
Upside: +566.67%
Mar 13, 2026
Reiterated: Buy
Price Target: $22
Current: $12.25
Upside: +79.59%
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $59.59
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $54.39
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $3.44
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $11.38
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $81.38
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $27.53
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $0.885
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $23.74
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $10.50
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $10.99
Upside: -
Sep 25, 2025
Rated: Hold
Price Target: n/a
Current: $1.24
Upside: -
Sep 23, 2025
Reiterated: Buy
Price Target: $75
Current: $47.78
Upside: +56.97%
Jan 29, 2024
Rated: Hold
Price Target: n/a
Current: $5.18
Upside: n/a
Jun 16, 2022
Initiated Coverage: Buy
Price Target: $77
Current: $303.39
Upside: n/a